echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Gilead Sciences has agreed to a $800 million partnership to create innovative cancer immunotherapy.

    Gilead Sciences has agreed to a $800 million partnership to create innovative cancer immunotherapy.

    • Last Update: 2020-09-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    JTX-1811 is a monoclonal antibody designed to selectively remove immunosuppressive tumor-immersive regulatory T (TITR) cells.
    target of JTX-1811 is CCR8, a chemical factor subject that is rich in TITR cells.
    when JTX-1811 binds to CCR8, it can target the removal of TITR cells through enhanced antibody-dependent cytotoxic mechanisms.
    antibody will submit an IND application in the first half of 2021.
    Jounce will be responsible for the early development of the JTX-1811 until IND approval is obtained, after which Gilead will have an exclusive interest in the development of the JTX-1811.
    resources: s1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved 2020-09-01, from.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.